Check for updates

OPEN ACCESS

EDITED BY Mustapha Najimi, Université catholique de Louvain, Belgium

REVIEWED BY Istvan Szatmari, University of Debrecen, Hungary Gufa Lin, Tongji University, China

*CORRESPONDENCE Geoffrey Brown, ⊠ g.brown@bham.ac.uk

SPECIALTY SECTION This article was submitted to Stem Cell Research, a section of the journal Frontiers in Cell and Developmental Biology

RECEIVED 08 March 2023 ACCEPTED 27 March 2023 PUBLISHED 04 April 2023

CITATION

Brown G (2023), Retinoic acid receptor regulation of decision-making for cell differentiation. *Front. Cell Dev. Biol.* 11:1182204. doi: 10.3389/fcell.2023.1182204

COPYRIGHT

© 2023 Brown. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retinoic acid receptor regulation of decision-making for cell differentiation

Geoffrey Brown*

School of Biomedical Sciences, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

All-trans retinoic acid (ATRA) activation of retinoic acid receptors (RARs) is crucial to an organism's proper development as established by findings for mouse foetuses from dams fed a vitamin A-deficient diet. ATRA influences decisionmaking by embryonic stem (ES) cells for differentiation including lineage fate. From studies of knockout mice, RARa and RARy regulate haematopoiesis whereby active $RAR\alpha$ modulates the frequency of decision-making for myeloid differentiation, but is not essential for myelopoiesis, and active RARy supports stem cell self-renewal and maintenance. From studies of zebrafish embryo development, active RARy plays a negative role in stem cell decision-making for differentiation whereby, in the absence of exogenous ATRA, selective agonism of RARy disrupted stem cell decision-making for differentiation patterning for development. From transactivation studies, 0.24 nM ATRA transactivated RAR γ and 19.3 nM (80-fold more) was needed to transactivate RARa. Therefore, the dose of ATRA that cells are exposed to in vivo, from gradients created by cells that synthesize and metabolize, is important to RAR γ versus RAR α and RAR γ activation and balancing of the involvements in modulating stem cell maintenance versus decision-making for differentiation. RARy activation favours stemness whereas concomitant or temporal activation of RAR γ and RAR α favours differentiation. Crosstalk with signalling events that are provoked by membrane receptors is also important.

KEYWORDS

retinoic acid receptors, vitamin A, stem cells, differentiation, haematopoiesis

Introduction

Vitamin A is required for the early development of many organs, including the eye, forelimbs, heart, hindbrain, posterior body axis, somites, and spinal cord (Clagett-Dame and Knutson, 2011; Berenger and Duester, 2022). ATRA, the most active metabolite of vitamin A, controls gene expression *via* the transcriptional activation of the three RAR types RARa, RAR β , and RAR γ . They, as a heterodimer with retinoid X receptor, bind to target gene retinoic acid response elements (RAREs) to drive transcription when ATRA binds to RARs. When ATRA is absent, DNA-bound RAR/RXR heterodimers are associated with corepressors which with recruited histone deacetylases maintain a condensed chromatin and repress gene expression (Chambon, 1996).

A key question was does the transcription action of ATRA depends entirely on RARs? To answer, investigators developed RAR α , RAR β , and RAR γ triple knockout murine embryonic stem (ES) cell lines and examined genome-wide transcription following treatment with ATRA for 24 and 48 h (Laursen and Gudus, 2018). ATRA did not affect the genome-wide transcriptional profile of the triple knockout ES cells. By contrast to wild type cells,

proliferation was not affected by ATRA, the induction of differentiation markers (Cyp26a1, Hoxa1, Cdx1, Stra8, CoupTF1 and Meis1) was abrogated, and the repression of stem cell markers (Nanog, Oct4, Zfp42, Sox2, Klf4, and Sall4) was perturbed. *Cyp26a1* and *Hoxa1* are RAR γ target genes (Kashyap et al., 2011; Kashyap et al., 2013) and ATRA failed to induce their expression within RAR γ knockout and RAR β and RAR γ double knockout cells (Laursen and Gudus, 2018). The transcriptional effects of ATRA and the capacity to decrease pluripotency markers, induce differentiation, and drive growth arrest are dependent on RARs. Even so, the biological functions of vitamin A and ATRA include non-genomic effects (Tanoury et al., 2013).

This review examines the roles of RARs in stem cell decisionmaking for cell differentiation from information gained from knockout mice and in vitro studies of ES cells and haematopoietic stem cells (HSCs). Regarding HSCs, various findings have challenged a longstanding model for how HSCs 'choose' to differentiate towards a mature cell type. Though new principles are still a matter of debate they are highly pertinent to consideration of how RARs influence HSC decision-making. In the conventional model of haematopoiesis, the progeny of HSCs undergoes a series of stepwise commitment decisions that eventually restrict intermediate progenitors to a single cell lineage. But HSCs can affiliate directly to a cell lineage as they are a heterogeneous population of cells as evidenced by the existence of megakaryocyte, erythroid, and macrophage lineage biased/ affiliated HSCs [reviewed in Brown, 2020]. HSCs "choose" to develop along a pathway from a continuum of all options (Ceredig et al., 2009). Their differentiation is a continuous process that lacks a definite point of commitment (Velten et al., 2017) because trajectories are broad and flexible and HSCs and progenitors that have adopted a lineage fate can still veer towards an alternative fate (Nestorowa et al., 2016). Cytokines play a key role in orchestrating lineage affiliation because erythropoietin and macrophage colony stimulating factor instruct erythroid and myeloid fate within HSCs, respectively (Grover et al., 2014; Mossadegh-Keller et al., 2013). Granulocyte colony-stimulating factor and macrophage colony-stimulating factor instruct granulocyte and macrophage fate within bipotent progenitors, respectively (Rieger et al., 2009; Metcalf and Burgess, 1982). Crosstalk between ATRA- and membrane receptor-provoked events has been known for some time from the negative crossmodulation between RARs and the activator protein 1 (AP-1), which regulates gene expression in response to cytokines (Nicholson et al., 1990). AP-1 has been implicated in the regulation of the erythropoietin-driven survival/proliferation of erythroid cells (Jacobs-Helber et al., 1998).

Findings from studies of the development of embryonic cells

Findings for RAR null mutant mice confirmed the importance of vitamin A to embryonic development and addressed whether RARs are essential transducers of ATRA signalling *in vivo*. The defects seen for double null mutant mice recapitulated the congenital malformations seen in foetuses from dams fed a vitamin A-deficient diet, and these null mutant mice displayed additional

abnormalities (Lohnes et al., 1994). Deletion of the whole RARa led to death of >90% of the homozygotes before the age of 2 months, but the mice failed to display any of the vitamin A deficiency-associated lesions other than testis degeneration. Mice null for the predominant RARa1 isoform appeared to be normal (Lufkin et al., 1993). Mice lacking all forms of RAR^β developed normally (Luo et al., 1995), and mice lacking the most abundant RARB2 isoform appeared to be normal (Mendelsohn et al., 1994). Mice null for all isoforms of RARy exhibited deficient growth, early lethality, squamous metaplasia of the seminal vesicles and prostate, and male sterility, and RARy2 null mice appeared to be normal (Lohnes et al., 1993). There is a degree of functional redundancy among the RARs. In keeping, RARy nullcells failed to differentiate in vitro in response to ATRA and express several ATRA-induced genes and re-expression of RARy or overexpression of RARa restored differentiation potential and target gene activation. RAR β restored target gene activation but poorly restored differentiation potential. ATRA-activation of Cdx1, Gap43, Stra4, and Stra6 was specifically impaired within RARy-null cells pointing to a distinct subset of target genes for RARy and for other RARs (Taneja et al., 1995).

Embryonic stem (ES) cells are competent regarding the production of all the cell types and ATRA has been used to obtain different cell types from mouse ES cells grown as monolayers or as hanging drops to form embryoid bodies. Cells resembling male germ cells spontaneously arise from embryoid bodies and treatment with 2 µM ATRA, with or without testosterone, significantly increased the expression of male germ cell lineage-associated genes. (Silva et al., 2009). The findings for the generation of neuronal cells vary according to the cells and conditions used. ATRA activates transcription of the Hoxa1 gene in ES cells and monolayer cultures of Hoxa1^{-/-} ES cells treated with ATRA expressed genes that are associated with embryonic brain development at a lower level than wild type cells. The reintroduction of exogenous Hoxa1 was needed for 5 µM ATRA-induced ES cell neuronal differentiation (Martinez-Ceballos and Gudas, 2008). Other investigators reported that 1 µM ATRA enhanced the efficiency of differentiation of ES cells into neural precursor cells (Li et al., 2019) and that this conversion required both fibroblast growth factor and the elimination of signals for other fates (Ying et al., 2003). Neural precursor cells have been efficiently derived from ES cells without the addition of ATRA by using a threedimensional culture system followed by two-dimensional derivation. The investigators used fibroblast growth factor and the B27 medium supplement containing retinyl acetate, which is a natural form of vitamin A (the acetate ester of retinol) and a precursor in ATRA metabolism (see below regarding the importance) (Yoon et al., 2021). A 100 nM concentration of ATRA has been used to induce the expression of mesodermal marker genes within mouse ES cells (Oeda et al., 2013).

The use of a pharmacological amount of ATRA $(1-5 \mu M)$ to differentiate ES cells is a concern. The affinities of ATRA for RARa, RAR β , and RAR γ are 9 nM, 3 nM, and 10 nM, respectively (Idres et al., 2002), and the physiological concentration of ATRA in tissues is ~1-10 nM (Czuba et al., 2020). ES cells are usually cultured in medium plus either foetal calf serum or the B27 supplement (Amit and Itskovitz-Elder, 2002; Sadhananthan and Touson, 2005) and they differentiate into cells that arise from the three germ cells layers. Medium with 10% foetal calf serum contains 50 nM all-*trans*-retinol and the level of ATRA in the serum of humans and other mammalians is ~ 4-14 nM (Baltes et al., 2004). As mentioned above, the B27 supplement contains retinyl acetate and ES cells cultured in the B27 supplemented medium synthesized ATRA and their differentiation towards neural precursor cells (expressing Sox1) was reliant on ATRA produced endogenously (Engberg et al., 2010). ATRA was not measurable and to demonstrate the need for neuronal differentiation the investigators either removed retinyl acetate from the B27 supplemented medium, inhibited the enzymes that catalyse the synthesis of ATRA, or used the pan-RAR antagonist AGN193109 to block the activity of RARs and neural differentiation was prevented. For retinyl acetate deprived cells, neuronal differentiation was restored by the addition of 1 nM ATRA. When ATRA signalling was inhibited, there was change of fate from neuronal to mesoderm and Nodal signalling had repressed neuronal development in a Wnt-dependent manner. The investigators concluded that a neuronal to mesoderm fate switch depends on active Nodal-, Wnt-, and FGF signalling. It is welldocumented that signalling via Nodal, a transforming growth factor β-related factor, and Wnt glycoproteins stimulation of complex intracellular signalling cascades play roles during organogenesis and ES cell differentiation (Schier and Shen, 2000; Takenaga et al., 2007; Koyima and Habas, 2008; Sokol, 2011).

The roles of individual RARs within mouse ES cells have been examined by homologous recombination disruption of the Rara and Rarg genes (Tanoury et al., 2014). ES cells were cultured as cellular aggregates and treated with 2 µM ATRA to generate neuronal cells. ES cells lacking RARa became neural progenitors, giving rise to neurons, cells lacking RARy failed to do so, and RARy2 rescued lines gave rise to neurons pointing to a role for RARy2 in ES cell neuronal development. From comparison of ATRA-induced gene expression by wild type and the RARy2 restored cells and RT-qPCR experiments, the investigators showed that RARy2 regulates a small number of genes, exemplified by meis homeobox 2 (Meis2), left right determination factor 1 (Lefty1), hepatocyte nuclear factor 1 homeobox B (Hnf1b), arginase 1, and the homeobox (Hox) genes Hoxa3, and Hoxa5. RARs are phosphorylated in response to ATRA and the importance of phosphorylation of RARy2 was investigated by expressing forms of RARy2 that had been modulated in phosphoacceptor sites. For ATRA-mediated neuronal differentiation, gene expression that was controlled by phosphorylation of RARy2 included that of Meis2, Lefty1, Hnf1b, and gastrulation brain homeobox 2. The genes targeted by phosphorylated RARy2 depicted atypical DR7 retinoic acid response elements in addition to canonical DR2 and DR5 elements and the phosphorylated form of RARy2 was recruited by DR7 and DR5 elements in response to ATRA. RARa1 was phosphorylated in vitro and in vivo by protein kinase A and phosphorylation at the site is involved in dibutyryl cAMP modulation of the differentiation of F9 embryonal carcinoma cells (Rochette-Egly et al., 1995).

Lessons from studies of ES cells are as follows. RAR γ 2 plays a role in ATRA-induced ES cell neuronal differentiation by either regulating the expression of specific genes or closing "unwanted" options regarding a proposed need. A physiological level (nM) of ATRA influences decision-making for differentiation including lineage fate. Endogenously produced ATRA plays a key role because vitamin A signalling is, in essence, driven by the intracellular ATRA concentration. In general, evaluation of the

effect of treating cells with ATRA is confounded by all-*trans*retinol or retinyl acetate in medium (Czuba et al., 2020) because of the need to take into consideration cryptic ATRA signalling from endogenous synthesis. Moreover, when epidermal keratinocytes were cultured in medium supplemented with 5% foetal calf serum, which contained 25 nM all-*trans* retinol and ATRA was undetectable, the level of all-*trans* retinol led to an intracellular level of ATRA of 25—50 nM (Randolph and Simon, 1997). This is well within the range of ATRA for activation of RARs. Growth factorprovoked signalling events are important to ES cell differentiation and RAR phosphorylation allows the relay of information from cellsurface receptor-provoked kinase cascades. Additionally, ATRA provoked non-transcription effects within differentiating mouse embryonic stem cells include the rapid and transient activation of kinase cascades [reviewed in Rochette-Egly, 2015].

Findings for RARα and haematopoietic cell differentiation

The RAR α gene is expressed in almost all adult tissues, and expression of the major isoform RARa1 is also ubiquitous (Leroy et al., 1991). During haematopoiesis, RAR α is expressed by HSCs and their differentiating offspring. Mouse lineage-negative, c-kit-positive, Sca-1-positive (LKS+) cells, that contain HSCs, and lineage-negative, c-kit-positive, Sca-1- negative (LKS-) cells, that lack HSCs, expressed RAR α (Purton et al., 2006). RAR α , particularly RAR α 2, expression increased dramatically during myeloid differentiation as seen for the induced differentiation of FDCP mixA4 mouse progenitor cells (Zhu et al., 2001). In addition to controlling homeostasis, RARs control the functional activity of some of the mature blood cells regarding the production of inflammatory cytokines [reviewed in Duong and Rochette-Egly, 2011]

A role for RARa in myeloid differentiation is well established (Collins, 2002). ATRA promotes the differentiation of promyeloid cell lines and normal myeloid progenitors and findings for the human promyeloid cell line HL-60 established a role for RARa in neutrophil differentiation. HL-60 cell differentiate towards neutrophils in response to treatment with ATRA (Breitman et al., 1980) and macrophages when treated with 1a,25-dihydroxyvitamin D3 (1,25D) to activate the vitamin D receptor (VDR) (Mangelsdorf et al., 1984). HL-60 cells undergo a low rate of spontaneous neutrophil differentiation because around 3%-10% of cells are more mature myelocytes, metamyelocytes, and banded and segmented neutrophils. A 1 µM concentration of ATRA promoted neutrophil differentiation with 90% of the cells terminally maturing, and 100 nM was effective. The identification of a PML-RARa fusion transcript in the cells from patients with acute promyelocytic leukaemia (de The et al., 1990) focused attention on RARa playing a key role during HL-60 neutrophil differentiation. Retroviral vector-mediated transduction of a single copy of RARa into an ATRA-resistant HL-60 subclone restored ATRA sensitivity for differentiation (Collins et al., 1990). Similarly, RARa agonism, by using AGN195183, was sufficient to promote HL-60 cell differentiation towards neutrophils (Brown et al., 2017). As mentioned above, G-CSF directs normal granulocyte/ macrophage progenitors towards neutrophils (Rieger et al., 2009)

and co-operates with ATRA to promote HL-60 differentiation towards neutrophils. Treatment of HL-60 cells with 10 nM ATRA led to a low level of neutrophil differentiation, differentiation was rapid and effective when 10 nM ATRA was combined with 30 ng/ml G-SCF, and G-CSF alone had no effect. A low dose of ATRA had rendered HL-60 cells responsive to the action of G-CSF (Sakashita et al., 1991; Bunce et al., 1994).

The influence of ATRA on neutrophil differentiation is particularly well-documented. ATRA and RARa also promote monocyte differentiation as shown from studies of the promyelocytic cell line NB4 and myeloblast blast-like cell line KG-1 (Brown et al., 2017). These cells express RARa and do not express RARy. For NB4cells, 100 nM of the RARa agonist promoted neutrophil differentiation (40% CD11b+/CD14-ve cells) and treatment with 10 nM 1,25D led to a low level of monocyte differentiation (CD11b+/CD14+ve and ~6%). The combined use of 100 nM of the RARa agonist and 10 nM 1,25D increased the level of monocyte differentiation (to ~50%). KG-1 cells differentiated towards neutrophils to a very small extent (~5%) in response to 100 nM of the RARa agonist and 10 nM 1,25D did not have a significant effect. Like NB4 cells, there was a significant level of monocyte differentiation (18%) when KG-1 cells were treated with the RARa agonist and 1,25D. RARs interact with several other nuclear receptors (Chambon, 1996) and the rationale to the interplay between the actions of the RARa agonist and 1,25D is that ATRA activation of RARa within NB4 and KG-1 cells upregulated the expression of a transcriptional variant of VDR that originates in exon 1a. KG-1 cells expressed RARa protein at a high level which in the absence of ATRA had repressed transcription of the VDR gene. The receptor interplay is complex and linked to cell status because ATRA downregulated VDR mRNA for HL-60 cells differentiating towards neutrophils in response to ATRA (Marchwicka et al., 2016).

For normal human bone marrow myeloid progenitor cells, ATRA supported their differentiation towards neutrophils but not towards erythrocytes (Gratas et al., 1993). Findings from in vitro cultures of cells from null mutant mice suggested roles for RARa1 and RARy in neutrophil maturation (Labrecque et al., 1998). This was normal within myeloid colonies that were grown in methylcellulose from the bone marrow cells harvested from RARa1 and RARy knockout mice. Neutrophil differentiation within myeloid colonies from cells harvested from the RARa1 and RARy double knockout mouse was blocked at the myelocyte stage. The differentiation of cells within erythroid and macrophage colonies was not affected. The distribution of neutrophils, macrophage, and erythroid colonies was the same for cells from the wild type mice and the RARa1, RARy, and compound null mutants, suggesting that lineage choice was not affected by a lack of RARa1 and/or RARy. By contrast, various studies have reported that ATRA-mediated enhancement of myeloid-colony growth associates with a reduced production of colonies containing cells of other lineages, suggesting an influence of ATRA on multipotent cells [reviewed in Collins, 2002].

The influence of ATRA on primitive mouse haematopoietic cells was different to that seen for myeloid progenitor cells. Like ES cells, mouse LSK + cells, which are enriched for HSCs, differentiate spontaneously in liquid suspension culture and treatment with $1 \mu M$ ATRA delayed their differentiation. LSK + cells were

allowed to differentiate for 7 days and then treated with 1 μ M ATRA. The effect of ATRA on committed progenitor cells arising from the cultured LSK + cells was as seen for normal human bone marrow myeloid progenitor cells and HL-60 cells. There was a markedly decreased level of colony-forming cells and enhanced neutrophil differentiation which was attributed to enhanced maturation of committed granulocyte/monocyte progenitors (Purton et al., 1999).

Dormant mouse HSCs metabolize all-trans retinol to ATRA in a cell-autonomous manner (Cabezas-Wallscheid et al., 2017) and the aldehyde dehydrogenases (ALDHs), a family of oxidoreductases, convert retinaldehyde into ATRA. The importance of endogenous retinoid metabolism to cultured mouse HSCs (CD34⁻ LSK+) was investigated by using diethylaminobenzaldehyde to inhibit ALDH activity. This impeded HSC differentiation leading to a ninefold expansion of HSCs, as measured by cells that were able to reconstitute lethally irradiated mice (Muramoto et al., 2010). Targeted siRNA of ALDH1a1 in HSCs revealed that this ALDH was the target of diethylaminobenzaldehyde inhibition. Similarly, inhibition of ALDH activity led to expansion of human HSCs that were able to repopulate NOD/SCID mice (Chute et al., 2006). From these studies, ALDH regulates HSC differentiation whereby the conversion of retinaldehyde into ATRA promotes HSC differentiation. Cyp26b1 is generally viewed as an enzyme that limits the effects of ATRA on cells by metabolising ATRA to 4oxo-retinoic acid. A recent omics analysis revealed that the maintenance of mouse HSCs was reliant on the production of 4oxo-retinoic acid and transmission of 4-oxo-retinoic acid-mediated signalling via RARB (Schonberger et al., 2022). 4-oxo-retinoic acid activates the three RARs and the level required for activation of RAR β is lower than that for RAR α and RAR γ (EC₅₀ values of 33 nM, 8 nM, and 89 nM, respectively) (Idres et al., 2002).

Purified human lineage-, CD133+, CD34+ cells are enriched for HSCs and the role of RARa was investigated by treating these cells with antagonists. Cell production peaked at day 20 for control cultures and viable cells then declined rapidly. The pan-RAR antagonist AGN194310 treated cultures were maintained for up to 55 days, with 4-fold more cells by day 40. Both cultures produced mostly neutrophils and monocytes, in equal ratios, with the antagonist treated cultures generating more of the two mature cell types (as to the increased cumulative cell number) (Brown et al., 2017). AGN194310-provoked increased myeloid cell production by HSCs is in keeping with neutrophil numbers were strikingly increased in mice treated with AGN194310 (Walkley et al., 2002) and that vitamin A deficiency in mice caused a systemic expansion of myeloid cells (Kuwata et al., 2000). CD11b+ differentiated myeloid cells appeared and immature myeloid cells declined at the same rates in both control and AGN194310 treated cultures. Switching-off RARs had not slowed down myeloid cell differentiation and instead there was enhanced expansion of lineage-, CD133+, CD34+ cells and colony-forming progenitors within the AGN194310 treated cultures. Antagonism of RARa, by AGN195183, was sufficient for the enhanced expansion of lineage-, CD133+, CD34+ cells and antagonising RARy did not lead to this enhancement. At first sight it seems paradoxical that antagonism of all RARs had delayed human HSCs differentiation and that agonism of all RARs (with ATRA) had delayed mouse LSK + cell differentiation (see above). The two cell populations are

different regarding their heterogeneity and the culture conditions used were different. Otherwise, the findings point to complex actions for RAR α and RAR γ . A lack of active RAR α (RAR α antagonism) had delayed the differentiation of human lineage-, CD133+, CD34⁺ cells whereas the presence of activated RAR γ (ATRA agonism) may have interfered with the differentiation of the mouse LSK + cells (see also later).

From studies of haematopoiesis, active RARa plays a role to enhance neutrophil differentiation of mouse progenitor cells and human HSCs and promyeloid cell lines. The role of RARa is to modulate/regulate rather than being essential for myelopoiesis (Kastner and Chan, 2001). For example, the terminal differentiation of cultures of human HSCs towards neutrophils and macrophages was unaffected when RARa was antagonised. For these cells, antagonism of RARa did not alter the relative proportions of neutrophils versus macrophages generated nor appeared to accelerate the terminal maturation of immature myeloid cells. Instead, active RARa positively modulated the frequency of decision-making for differentiation to favour differentiation. In other words, unliganded interferes with gene expression for differentiation which is promoted when ATRA or a specific RARa agonist is bound (Kastner and Chan, 2001; Collins, 2002). G-CSF is a key regulator of granulopoiesis and, like RARa, was dispensable. The combined action of these agents was investigated by conditional deletion of RARa on a G-CSF receptor-null background and treating G-CSF receptor null mice with the pan-RAR antagonist AGN194310 (referred to as NRX194310); granulopoiesis persisted in these mice (Chee et al., 2013). To differentiate or not is a multifactorial decision and the following section examines the extent to which RARy plays a role in decision-making for cell differentiation.

Findings for RAR γ and cell differentiation

Unlike RAR α , the distribution of RAR γ is very restricted and specific spatial and temporal distributions of RAR γ during mouse embryogenesis led to the proposal that RAR γ plays a role in early morphogenic events (Ruberte et al., 1990). During haematopoiesis, RAR γ is selectively expressed by hematopoietic stem cells and primitive progenitors (Purton et al., 2006). In keeping with a restricted expression of RAR γ within primitive cells, the binding sites for RAR/RXR dimers within undifferentiated F9 embryonal carcinoma cells coincided with loci that are targeted by transcription factors that are important to pluripotency (SOX2, NANOG, and POU5f1) (Chatagnon et al., 2015).

A special consideration to the role of RAR γ versus that of RAR α is the level of ATRA that cells are exposed to influences whether RAR γ or RAR γ together with RAR α are transactivated within cells. The concentration of ATRA that is needed to activate RAR γ is substantially lower than that required for activation RAR α . A 0.24 nM level of ATRA transactivated RAR γ whereas 19.3 nM (80-fold more) was needed to transactivate RAR α (Brown et al., 2017). By contrast, the best ATRA induction of transcription was obtained for RAR α which was 10-fold higher than that for RAR γ , as seen from the fold-induction of luciferase activity from a RARE-tk-Luc reporter plasmid in the presence of each RAR (Idres et al., 2002). The increased fold induction by RARa suggests a greater efficiency to inducing transcription as governed by the interaction of the ligand-activated receptor complex with response elements.

The nature of the genes that are regulated by RARy is germane to consideration of a role for RARy. Comparison of ATRA-induced events within the wild type and RARy null ES cells showed that RARy is essential for ATRA-induced epigenetic marks at gene promoters, chromatin remodelling, and transcriptional activation. ATRA activation of RARy greatly increased the transcript levels of genes that encode regulators of ATRA metabolism within cells. They were the genes encoding stimulated by retinoic acid 6 (Stra6), lecithin:retinol acyltransferase (LRAT), cellular retinoic acid binding protein 2 (CRABP2), and cytochrome p450 26A1 (CYP26A1) (Kashyap et al., 2013). Retinol-binding protein 4 (RBP4) transports all-trans retinol (vitamin A) in the blood for transfer into cells which is mediated by binding to Stra6. LRAT converts all-trans retinol into retinyl esters for storage, CRABP2 delivers ATRA to the nucleus and RARs, and CYP26A1 catabolises ATRA to polar metabolites for elimination. RARy expression by stem cells might autoregulate a low ATRA content by virtue of ATRA activation leading to the diversion of "excess" all-trans retinol into retinyl esters for storage and elevated CYP26A1 expression increasing ATRA breakdown. These controls on ATRA-driven RAR events may be an important "housekeeping" function to stem cell stemness. From the studies of ATRA-regulated genes in the early zebrafish embryo, CYP26A1 was identified as one of the most robust genes regarding ATRA regulation, even when ATRA availability is drastically reduced (Samarut et al., 2014), and, as above, RARy is transactivated by sub nM ATRA. A proposal from the zebrafish studies was also that RARy subtypes appeared to play roles in the basal regulation of ATRA-responsive gene expression with RARa subtypes playing roles in the transcriptional response of cells to ATRA. (Samarut et al., 2014).

The above considerations point to active RAR γ promoting stem cell maintenance and stemness. Indeed, RAR γ plays a critical role in balancing HSC self-renewal/maintenance *versus* differentiation (Purton et al., 2006). The bone marrow of RAR γ knockout mice had markedly reduced numbers of HSCs, measured as transplantable repopulating cells per femur, and the numbers of mature myeloid progenitors were increased. *Ex vivo* activation of RAR γ , by ATRA, promoted the self-renewal of HSCs because loss of RAR γ abrogated the capacity of ATRA to enhance the maintenance of HSCs in culture. Regarding stem cell stemness, a much more undifferentiated phenotype was seen for primitive haematopoietic precursors that were retroviral-mediated transduced to overexpress RAR γ whereas primitive precursors that overexpressed RAR α differentiated predominantly to granulocytes.

As considered above, RAR γ 2 has a role in specifying ES cell neuronal differentiation which might relate to either a positive influence or the proposed need for the elimination of other fates (Ying et al., 2003). Studies of zebrafish embryos revealed a negative role for active RAR γ in cell differentiation. RAR γ transcripts are restricted to primitive cells at the later stages of the zebrafish embryo. At 24 h post fertilisation they were restricted to mesodermal and neural crest stem and progenitor cells, in the head area, in the lateral plate mesoderm, and in the pre-somitic mesoderm of the tail bud. Transcripts were still visible in the tail bud at 48 h post fertilisation (Hale et al., 2006). Zebrafish embryos were



FIGURE 1

Controls on stem cell stemness Active RAR γ is required for the maintenance of HSCs, for zebrafish embryos activation disrupted stem cell decision-making for differentiation for the patterning of development, and RAR γ plays a role in regulating pluripotency genes. Genes that regulate the intracellular level of ATRA are expressed upon RAR γ transactivation whereby lecithin:retinol acyltransferase (LRAT) converts all-*trans* retinol to retinyl esters for storage and cytochrome p450 26A1 (CYP26 A1) catabolizes ATRA. A sub nM intracellular level is sufficient to transactivate RAR γ .

treated at 4 h post fertilisation (hpf) with 10 nM of the RARyselective agonist AGN205327. This dose of the agonist is close its binding affinity for RAR γ (an ED₅₀ of 32 nM). Treatment led to the development of viable fish that were substantially abnormal. There were substantial changes to head morphology, associated with loss of cranial bones and tissue, a reduced antero-posterior axis length, due to somite loss, and heart abnormalities that led to oedema. Regarding the loss of cranial bones and anterior line ganglia, the prevalence of Sox-9 neural crest cells was not affected other than a slight decrease in the head region. The agonist prevented caudal and pectoral fin formation and Tbx5a progenitors that form the pectoral fin were present in the bud region. The lack of pectoral outgrowth, provoked by the RARy agonist at 4 hpf, was reversed by the addition, at 23 h post fertilization, of a RARy antagonist, to reverse the action of the RARy agonist, or wash out of the RARy agonist at 23 h. The experiments were performed in E3 medium (for zebrafish embryos) which is a balanced salt solution. Therefore, and in the absence of exogenous ATRA, agonising RARy had disrupted stem cell decisionmaking for differentiation for the patterning of zebrafish development. The option for fin development had been sustained within bud stem cells as to the reversibility of the action of the RARy agonist (Wai et al., 2015). Regarding reversibility, it is noteworthy, as mentioned above, that RARy regulates ATRA-induced chromatin epigenetic marks for gene expression within ES cells (Kashyap et al., 2013).

Controls on stem cell decision-making

The maintenance of stem cells is crucial to an organism to meet the need to replace any damaged and worn-out cells throughout life. The controls that ensure a pool of stem cells are likely to be multiple, and, therefore, rigorous. The presence of active RAR γ regulates the



for ATRA, concomitant treatment of P19 and F9 embryonal carcinoma cells with RAR $_{\alpha}$ and RAR $_{\gamma}$ agonists at receptor-selective concentrations favoured differentiation, whereas each agent when used alone failed to promote differentiation. Crosstalk with other signalling events is important, for example, fibroblast growth factor (FGF) for ES cells and the lineage instructive haematopoietic cytokines.

maintenance of stem cell stemness because pluripotency genes are direct targets of RARy. A sub-nM concentration of ATRA is sufficient for transactivation of RARy. A higher level of ATRA is needed to transactivate RARa, to favour decision-making for differentiation. Stem cells may protect themselves from differentiation that is favoured by RARa activation, by a higher level of ATRA, by means of RARy-mediated upregulation of the expression of LRAT, for the storage of all-trans retinol, and CYP26, for the degradation of ATRA (Figure 1). Regarding a low intracellular level of ATRA within stem cells, it has been proposed that ES cells do not have all the enzymes that are needed to metabolise all-trans retinol into ATRA (Chen and Khillan, 2010; Khillan, 2014). Instead, all-trans retinol has been proposed to play a role in promoting the self-renewal of ES cells by the direct activation of the phosphoinositide 3 kinase/Akt signalling pathway via insulin-like growth factor-1.

ATRA was used at a dose that activates RAR α and RAR γ for *in vitro* differentiation of the cells considered above. Studies have examined the effect of treating P19 and F9 embryonal carcinoma cells with a combination of the synthetic RAR α - and RAR γ -selective agonists Am80 and CD666, respectively (Roy et al., 1995). As seen for ATRA activation of RAR α and RAR γ , treatment of P19 cells with non-selective concentrations of AM80 and CD666, for activation of both RAR α and RAR γ , induced expression of the *Stra1*, *Stra2*, *CRABPII*, *RAR\beta* and *Hoxa-1* genes. *Stra1*, *Stra2*, and *CRABPII* were not induced when Am80 and CD666 were used separately at a receptor-selective concentration, and the induction of *RAR\beta* and *Hoxa-1* was substantially reduced. The combined use of receptor-selective concentrations of AM80 and CD666 led to inductions.

Similarly, P19 cells differentiated when treated with Am80 and CD666 when each agonist was used at a non-selective concentration, they failed to do so when each agonist was used at a receptor-selective concentration, and the combined use of receptor-selective concentrations of Am80 and CD666 led to differentiation The findings for F9 cells were similar other than the combinations of compounds appeared to be less efficient. The differentiation provoked by the combined use of agonists at receptor-selective concentrations was viewed as an additive/ synergistic action and support to functional redundancy regarding RARa and RARy. Alternatively, from these studies and the potent differentiating effects of ATRA the concomitant or temporal activation of both RARa and RARy favours decisionmaking for differentiation in a more complex manner. Regarding complexity, RAR/RXR binding elements can distinguish pluripotency-from differentiation-associated genes which appears to be mediated by different sets of regulatory regions, with DR0containing regions favoured in undifferentiated and DR5-enriched in differentiated cells (Chatagnon et al., 2015).

There are additional controls on decision-making for differentiation that include signalling events that are provoked by, for example, FGF for ES cells and the hematopoietic cytokines that instruct cell lineage (Figure 2). The importance of cytokines is emphasised by studies of HSCs derived from ES cells. Human HSCs (CD34⁺) cells were efficiently derived from ES cells by coculture with OP9 bone marrow stromal cells. When isolated cells were cultured on MS-5 stromal cells with the addition of stem cell factor, Flt-3 ligand, interleukin 7 (IL-7), and IL-3 they generated granulocytes, macrophages, B-cell, and natural killer cells (Vodyanik et al., 2005). Similarly, the treatment of human ES cells with a combination of cytokines and bone morphogenic protein-4 promoted the differentiation of hematopoietic progenitors. The cells generated included colony-forming units for granulocytes, macrophages, and erythrocytes together with multipotent colonyforming units (Chadwick et al., 2003).

RAR α and RAR γ controls on decision making and cancer

Cancer is a decision-making process whereby cancer stem cells (CSCs) generate the hierarchy of developing cells to sustain a cancer (Dick, 2008). CSCs appear to arise largely from the malignant transformation of a tissue-specific stem cell and are, therefore, immortal [reviewed in Brown, 2022]. Often, the progeny of CSCs undergoes partial differentiation and belongs to a cell lineage; cancers are categorized according to the resemblance of the bulk cells to a cell type. Support to the lineage restriction of the progeny of CSCs has been provided by the findings from transgenic mice whereby restriction of an oncogenic insult to HSCs/haematopoietic progenitors led to restriction of the lineage options of CSCs or introduced a bias (Gonzales-Herrero et al., 2018).

A role for the fusion gene PML-RAR α in the pathogenesis of acute promyelocytic leukaemia is well established (de The et al., 1990). For nine acute promyelocytic patients, fusions have been described between RAR γ and the genes for PML, NUP98, CPSF6 and NPM1, and these patients failed to respond to

ATRA except for the one patient with the PML-RAR γ fusion (Conserva et al., 2019). A recent global study identified 34 patients with RAR γ rearrangements, the partner genes were diverse, and the rearrangement conferred a poor prognosis (Zhu et al., 2023).

From the importance of RARy to decision-making by stem cells, we might expect RARy to be an oncogene. RARy overexpression has been reported for good proportions of patients with cholangiocarcinoma, clear cell renal cell carcinoma, colorectal cancer, ovarian cancer, and pancreatic ductal adenocarcinoma. For cholangiocarcinoma, overexpression was associated with poor differentiation and metastasis to lymph nodes and contributed to multidrug resistance. Findings suggested that the role of RARy is mediated via activation of the Akt/NFkB and Wnt/B-catenin pathways and upregulation of P glycoprotein (Huang et al., 2013). RARy and RAR β were upregulated in clear renal cell carcinoma, as seen from a bioinformatics analysis and the use of quantitative PCR (Kudryavtseva et al., 2016). For colorectal cancer, RARy overexpression was linked to multidrug resistance with knockdown leading to downregulation of multi-drug resistance 1 and suppression of the Wnt/ β -catenin pathway (Huang et al., 2017). High expression on ovarian cancer was a predictor of poor overall survival outcomes and has been linked to accelerated disease progression via the regulation of cell proliferation (Xiu et al., 2022). Overexpression of RARy in pancreatic ductal adenocarcinoma tissue and high-grade precancerous lesions was linked to a poor patient prognosis and blocking RARy signalling supressed the proliferation of cancer cells (Yamakowa et al., 2022). For the above carcinomas, a common denominator was that a high level of expression of RARy was linked to a poor prognosis. Targeting RARy to treat disease is a promising prospect because for prostate cancer, agonism of RARy stimulated the growth of and colony formation by prostate cancer cell line cells and antagonising led to necroptosis of the cell line colony forming CSC-like cells and patients' cells (Petrie et al., 2022). The pan-RAR antagonist AGN194310 was also effective in ablating the formation of neurosphere-like structures by the CSCs of two paediatric patients' primitive neuroectodermal tumours and a paediatric patient's astrocytoma and killed the progeny of CSCs (Brown and Petrie, 2012). The extent to which increased expression of RARy and imbalance to the levels of expression of RARy and RARa had led to the development of the above carcinomas by deregulating the behaviour of CSCs is still unclear. Overexpression of RARy may play a role to maintain CSCs or to restrict these cells to a particular cell lineage. The latter is an intriguing consideration in view of the role of RARy2 in ES neuronal differentiation and perhaps the need to eliminate other fates (Ying et al., 2003), agonising RARy interfered with patterning for zebrafish development (Wai et al., 2015), and the need for RARy for chromatin epigenetic marks (Kashyap et al., 2013). Regarding epigenetic marks, RARy was identified as the predominant mediator of ATRA-mediated signalling within ES cells for activation of the Hoxa and Hoxb gene clusters. It was required for broad epigenomic organisation and necessary for the gene-specific removal of the polycomb repressive mark H3K27me3 during ES cell differentiation. Hox gene cluster reorganisation was triggered by RARy located at the Hoxa1 3'-RARE and deletion of the RARy binding site within the Hoxa1 enhancer attenuated epigenomic activation of Hoxa and Hoxb gene structures (Kashyap et al., 2011).

Perspectives and conclusion

Distinct ATRA gradients and boundaries, from cells that synthesize and metabolize, are important to patterning embryogenesis, but there does not appear to be a linear relationship between dose and phenotype (Bernheim and Meilhac, 2020). Gradients and the dose of ATRA that stem cells and their progeny are exposed is relevant to decision-making because sub nM ATRA is sufficient to activate RARy with RARa activation needing substantially more. Stem cells are equipped to store and degrade ATRA and seem unable to synthesize which may provide protection from ATRA-modulation of the frequency of decision-making for differentiation. RARy activation is important to the maintenance of HSCs and their stemness and activation, in the absence of active RARa, interfered with decision-making by zebrafish embryonic stem cells for differentiation. The level of ATRA that is used routinely to drive the differentiation of ES cells and other cells, which express both RARy and RARa, activates both RARa and RARy and concomitant or temporal activation of these receptors favors differentiation. Stem cell differentiation is a continuous and progressive process which might favour a temporal interaction(s), but whether concomitant or temporal is yet unclear. Expression of RARy decreases as stem cells differentiate leaving RARa to exert a sole influence on the progression of differentiation.

The roles of RARa and RARy are modulatory, rather than obligatory, which raises the question what is nature of the events that are being modulated. Signalling via growth factors and hematopoietic cytokines provide a further input to ES cell and HSC decision-making for cell differentiation, respectively. That stem cell differentiation is a progressive and gradual process presumably requires learning and memory of the events that are provoked by growth factors/cytokines. There is evidence to support integration of ATRA signalling with how cells learn from the events that are provoked by growth factors because CRABP1 delivers ATRA to the CYP26 family members for degradation and such dampens the sensitivity of ES cells to growth factors to affect their learning and memory (Nagpal and Wei, 2019). An intriguing possibility is whether RARa and/or RARy are modulatory by virtue of influencing the retention or loss of cell learning and memory for stemness and decision-making for differentiation. The epigenome has been proposed as the judge, jury, and executioner of stem cell fate (Tollervey and Lunyak, 2012). As above, RARy is needed for ATRA-induced chromatin epigenetic marks [Kashyap et al., 2012], and memory/learning are written within the epigenome by marks.

References

Amit, M., and Itskovitz-Elder, J. (2002). Derivation and spontaneous differentiation of human embryonic stem cells. J. Anat. 200, 225–232. doi:10.1046/j.1469-7580.2002.00032.x

Baltes, S., Nau, H., and Lampen, A. (2004). All-trans retinoic acid enhances differentiation and influences permeability of intestinal Caco-2 cells under serum-free conditions. *Dev. Growth Differ.* 46, 503–514. doi:10.1111/j.1440-169x.2004.00765.x

Berenger, M., and Duester, G. (2022). Retinoic acid, RARs and early development. J. Mol. Endocrinol. 69, T59-T67. doi:10.1530/JME-22-0041

Bernheim, S., and Meilhac, S. M. (2020). Mesoderm patterning by a dynamic gradient of retinoic acid signalling. *Philos. Trans. R. Soc. Lond. B Boil. Sci.* 375, 20190556. doi:10. 1098/rstb.2019.0556

Presently, we know how RARs work as heterodimers with RXRs, how they bind to response elements, that they repress gene expression in the absence of ligand and drive expression when ligand is bound, and that the RAR subtypes can regulate sub-sets of genes. However, the more complete picture regarding how all of this modulates the specification of cell lineage and/or the switch from stem cell maintenance to the onset of differentiation is still a complex and unresolved puzzle. Considerations include the extent to which ATRA is synthesized endogenously, which though cryptic is at a physiological level, the provision of ATRA by neighbouring cells including from gradients, which is again physiological, whether RAR α and/or RAR γ are activated, and crosstalk with other cytokine-provoked signalling cascades including phosphorylation of RARs.

Author contributions

GB wrote the manuscript.

Funding

This project received funding from the European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreement no 315902. GB was the lead within the Marie Curie Initial Training Network DECIDE.

Conflict of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Breitman, T. R., Selonick, S. E., and Collins, S. J. (1980). Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc. Natl. Acad. Sci. U. S. A.* 77, 2936–2940. doi:10.1073/pnas.77.5.2936

Brown, G., and Petrie, K. (2012). The RAR γ oncogene: An Achilles heel for some cancers. Int. J. Mol. Sci. 22, 3632. doi:10.3390/ijms22073632

Brown, G., Marchwicka, A., Cunningham, A., Toellner, K-M., and Marcinkowska, E. (2017). Antagonizing retinoic acid receptors increases myeloid cell production by cultured human hematopoietic stem cells. Arch. Immunol. Ther. Exp. 65, 69–81. doi:10.1007/s00005-016-0411-0

Brown, G. (2020). Towards a new understanding of decision-making by hematopoietic stem cells. Int. J. Mol. Sci. 21, 2362. doi:10.3390/ijms21072362

Brown, G. (2022). Hematopoietic and chronic myeloid leukemia stem cells: Multistability versus lineage restriction. *Int. J. Mol. Sci.* 23, 13570. doi:10.3390/ijms232113570

Bunce, C. M., French, P. J., Durham, J., Stockley, R. A., Michell, R. H., and Brown, G. (1994). Indomethacin potentiates the induction of HL60 differentiation to neutrophils, by retinoic acid and granulocyte colony-stimulating factor, and to monocytes, by vitamin D3. *Leukemia* 8, 595–604.

Cabezas-Wallscheid, N., Buettner, F., Sommerkamp, P., Klimmeck, D., Ladel, L., Thalheimer, F. B., et al. (2017). Vitamin A-retinoic acid signaling regulates hematopoietic stem cell dormancy. *Cell.* 169, 807–823.e19. doi:10.1016/j.cell.2017. 04.018

Ceredig, R., Rolink, A. G., and Brown, G. (2009). Models of haematopoiesis: Seeing the wood for the trees. *Nat. Rev. Immunol.* 9, 293–300. doi:10.1038/nri2525

Chadwick, K., Wang, L., Li, L., Menendez, P., Murdock, B., Roulleau, A., et al. (2003). Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. *Blood* 102, 906–915. doi:10.1182/blood-2003-03-0832

Chambon, P. (1996). A decade of molecular biology of retinoic acid receptors. *FASEB J.* 10, 940–954. doi:10.1096/fasebj.10.9.8801176

Chatagnon, A., Veber, P., Marin, V., Bede, J., Triqueneaux, G., Semon, M., et al. (2015). RAR/RXR binding dynamics distinguish pluripotency from differentiation associated cis-regulatory elements. *Nucleic Acid. Res.* 43, 4833–4854. doi:10.1093/ nar/gkv370

Chee, L. C., Hendy, J., Purton, L. E., and McArthur, G. A. (2013). The granulocytecolony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiation. *J. Leukoc. Biol.* 93, 235–243. doi:10. 1189/jlb.1211609

Chen, L., and Khillan, J. S. (2010). A novel signaling by vitamin A/retinol promotes self renewal of mouse embryonic stem cells by activating PI3K/Akt signaling pathway via insulin-like growth factor-1 receptor. *Stem Cells* 28, 57–63. doi:10.1002/stem.251

Chute, J. P., Muramoto, G. G., Whitesides, J., Calvin, M., Safi, R., Chao, N. J., et al. (2006). Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. *Proc. Natl. Acad. Sci. U. S. A.* 103, 11707–11712. doi:10.1073/pnas.0603806103

Clagett-Dame, M., and Knutson, D. (2011). Vitamin A in reproduction and development. *Nutrients* 3, 325–428. doi:10.3390/nu3040385

Collins, S. J., Robertson, K., and Mueller, L. (1990). Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). *Mol. Cell. Biol.* 10, 2154–2163. doi:10.1128/mcb.10.5.2154

Collins, S. J. (2002). The role of retinoids and retinoic acid receptors in normal hematopoiesis. *Leukemia* 16, 1896–1905. doi:10.1038/sj.leu.2402718

Conserva, M. R., Redavid, I., Anelli, L., Zagaria, A., Specchia, G., and Albano, F. (2019). RARG gene dysregulation in acute myeloid leukemia. *Front. Mol. Biosci.* 6, 114. doi:10.3389/fmolb.2019.00114

Czuba, L. C., Zhang, G., Yabat, K., and Isoherranen, N. (2020). Analysis of vitamin A and retinoids in biological matrices. *Methods Enzymol.* 637, 309–340. doi:10.1016/bs. mie.2020.02.010

de Thé, H., Chomienne, C., Lanotte, M., Degos, L., and Dejean, A. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. *Nature* 347, 558–561. doi:10.1038/347558a0

Dick, J. E. (2008). Stem cell concepts renew cancer research. *Blood* 112, 4793–4807. doi:10.1182/blood-2008-08-077941

Duong, V., and Rochette-Egly, C. (2011). The molecular physiology of nuclear retinoic acid receptors. From health to disease. *Biochim. Biophys. Acta* 1812, 1023–1031. doi:10.1016/j.bbadis.2010.10.007

Engberg, N., Kahn, M., Peterson, D. R., Hanson, M., and Serup, P. (2010). Retinoic acid synthesis promotes development of neural progenitors from mouse embryonic stem cells by suppressing endogenous Wnt-dependent nodal signaling. *Stem Cells* 28, 1498–1509. doi:10.1002/stem.479

Gonzales-Herrero, I., Rodriguez-Hernandez, G., Luengas-Martinez, A., Isidro-Hernandez, M., Jimenez, R., Garcia-Cenader, M. B., et al. (2018). The making of leukemia. *Int. J. Mol. Sci.* 19, 1494. doi:10.3390/ijms19051494

Gratas, C., Menot, M. L., Dresch, C., and Chomienne, C. (1993). Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. *Leukemia* 7, 1156–1162.

Grover, A., Mancini, E., Moore, S., Mead, A. J., Atkinson, D., Rasmussen, K. D., et al. (2014). Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate. *J. Exp. Med.* 211, 181–188. doi:10.1084/jem.20131189

Hale, L. A., Tallafuss, A., Yan, Y.-L., Dudley, L., Eisen, J. S., and Postlethwait, J. H. (2006). Characterization of the retinoic acid receptor genes raraa, rarab and rarg during zebrafish development. *Gene Expr. Patterns* 6, 546–555. doi:10.1016/j.modgep.2005. 10.007

Huang, G. L., Luo, Q., Rui, G., Zhang, W., Zhang, Q. Y., Chen, Q. X., et al. (2013). Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/ NF- κ B and Wnt/ β -catenin pathways in cholangiocarcinoma. *Mol. Cell. Biol.* 33, 3416–3425. doi:10.1128/MCB.00384-13 Huang, G. L., Song, W., Zhou, P., Fu, Q. R., Lin, C. L., Chen, Q. X., et al. (2017). Oncogenic retinoic acid receptor γ knockdown reverses multi-drug resistance of human colorectal cancer via Wnt/ β -catenin pathway. *Cell. Cycle* 16, 685–692. doi:10.1080/15384101.2017.1295180

Idres, N., Marill, J., Flexer, M. A., and Chabot, G. G. (2002). Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers. *J. Biol. Chem.* 277, 31491–31498. doi:10.1074/jbc.M205016200

Jacobs-Helber, S. M., Wickrema, A., Birrer, M. J., and Sawyers, S. T. (1998). AP1 regulation of proliferation and initiation of apoptosis in erythropoietindependent erythroid cells. *Mol. Cell. Biol.* 18, 3699–3707. doi:10.1128/MCB.18. 7.3699

Kashyap, V., Gudas, L. J., Brenet, F., Funk, P., Viale, A., and Scandura, J. M. (2011). Epigenomic reorganization of the clustered Hox genes in embryonic stem cells induced by retinoic acid. *J. Biol. Chem.* 286, 3250–3260. doi:10.1074/jbc.M110.157545

Kashyap, V., Laursen, K. B., Brenet, F., Viale, A. J., Scandura, J. M., and Gudas, L. J. (2013). RAR is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells. *J. Cell. Sci.* 126, 999–1008. doi:10. 1242/jcs.119701

Kastner, P., and Chan, S. (2001). Function of RARalpha during the maturation of neutrophils. *Oncogene* 20, 7178–7185. doi:10.1038/sj.onc.1204757

Khillan, J. S. (2014). Vitamin A/retinol and maintenance of pluripotency of stem cells. *Nutrients* 6, 1209–1222. doi:10.3390/nu6031209

Koyima, Y., and Habas, R. (2008). Wnt signal transduction pathways. Organogenesis 4, 68-75. doi:10.4161/org.4.2.5851

Kudryavtseva, A. V., Nyushko, K. M., Zaretsky, A. R., Shagin, D. A., Kaprin, A. D., and Yakovlevich Alekseev, B. (2016). Upregulation of rarb, rarg, and rorc genes in clear cell renal cell carcinoma. *Biomed. Pharmacol. J.* 9, 967–975. doi:10.13005/bpj/1036

Kuwata, T., Wang, I.-M., Tamara, T., Pannamperuma, R. H., Levine, R., Holmes, K. L., et al. (2000). Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. *Blood* 95, 3349–3356. doi:10.1182/blood.v95.11.3349

Labrecque, J., Allan, D., Chambon, P., Iscove, N. N., Lohnes, D., and Hoang, T. (1998). Impaired granulocytic differentiation *in vitro* in hematopoietic cells lacking retinoic acid receptors a1 and γ . *Blood* 92, 607–615. doi:10.1182/blood.v92.2.607.414k06_ 607_615

Laursen, K. B., and Gudus, L. J. (2018). Combinatorial knockout of RARa, RAR β , and RAR γ completely abrogates transcriptional responses to retinoic acid in murine embryonic stem cells. *J. Biol. Chem.* 293, 11891–11900. doi:10.1074/jbc.RA118.001951

Leroy, P., Krust, A., Zelent, A., Mendelsohn, C., Gamier, J. M., Kastner, P., et al. (1991). Multiple isoforms of the mouse retinoic acid receptor alpha are generated by alternative splicing and differential induction by retinoic acid. *EMBOJ* 10, 59–69. doi:10. 1002/j.1460-2075.1991.tb07921.x

Li, Y., Mao, X., Zhao, X., Su, Y., Zhou, X., Shi, K., et al. (2019). An optimized method for neuronal differentiation of embryonic stem cells *in vitro*. *J. Neurosci. Methods* 330, 108486. doi:10.1016/j.jneumeth.2019.108486

Lohnes, D., Kastner, P., Dierich, A., Mark, M., LeMeur, M., and Chambon, P. (1993). Function of retinoic acid receptor gamma in the mouse. *Cell*. 73, 643–658. doi:10.1016/ 0092-8674(93)90246-m

Lohnes, D., Mark, M., Mendelsohn, C., Dolle, P., Dierich, A., Gorry, P., et al. (1994). Function of the retinoic acid receptors (RARs) during development (I). Craniofacial and skeletal abnormalities in RAR double mutants. *Development* 120, 2723–2748. doi:10. 1242/dev.120.10.2723

Lufkin, T., Lohnes, D., Mark, M., Dierich, A., Gony, P., Gaub, M-P., et al. (1993). High postnatal lethality and testis degeneration in retinoic acid receptor a mutant mice. *Proc. Nat. Acad. Sci. U. S. A.* 90, 7225–7229. doi:10.1073/pnas.90.15.7225

Luo, T., Pasceri, P., Conlon, R. A., Rossant, J., and Giguere, V. (1995). Mice lacking all isoforms of retinoic acid receptor β develop normally and are susceptible to the teratogenic effects of retinoic acid. *Mech. Dev.* 53, 61–71. doi:10.1016/0925-4773(95) 00424-6

Mangelsdorf, D. J., Koeffler, H. P., Donaldson, C. A., Pike, J. W., and Haussler, M. R. (1984). 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor-mediated maturation to macrophage like cells. *J. Cell. Biol.* 98, 391–398. doi:10.1083/jcb.98.2.391

Marchwicka, A., Cebrat, M., Lasziewicz, A., Sniezewski, L., Brown, G., and Marcinkowska, E. (2016). Regulation of vitamin D receptor expression by retinoic acid receptor alpha in acute myeloid leukemia cells. *J. Steroid Biochem. Mol. Biol.* 159, 121–130. doi:10.1016/j.jsbmb.2016.03.013

Martinez-Ceballos, E., and Gudas, L. J. (2008). Hoxal is required for the retinoic acidinduced differentiation of embryonic stem cells into neurons. *J. Neurosci. Res.* 86, 2809–2819. doi:10.1002/jnr.21729

Mendelsohn, C., Mark, M., Dolle, P., Dierich, A., Gaub, M. P., Krust, A., et al. (1994). Retinoic acid receptor beta 2 (RAR beta 2) null mutant mice appear normal. *Dev. Biol.* 166, 246–258. doi:10.1006/dbio.1994.1311

Metcalf, D., and Burgess, A. W. (1982). Clonal analysis of progenitor cell commitment of granulocyte or macrophage production. *J. Cell. Physiol.* 111, 275–283. doi:10.1002/jcp.1041110308

Mossadegh-Keller, N., Sarrazin, S., Kandalla, P. K., Espinosa, L., Stanley, E. R., Nutt, S. L., et al. (2013). M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. *Nature* 497, 239–243. doi:10.1038/nature12026

Muramoto, G. G., Russell, J. L., Safi, R., Salter, A. B., Himberg, H. A., Dahler, P., et al. (2010). Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. *Stem Cells* 28, 523–534. doi:10.1002/stem.299

Nagpal, I., and Wei, L-N. (2019). All-trans retinoic acid as a versatile cytosolic signal modulator mediated by CRABP1. *Int. J. Mol. Sci.* 20, 3610. doi:10.3390/ijms20153610

Nestorowa, S., Hamey, F. K., Pijuan Sala, B., Diamanti, F., Shepherd, M., Laurenti, E., et al. (2016). A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. *Blood* 128, e20–e31. –e31. doi:10.1182/blood-2016-05-716480

Nicholson, R. C., Maders, S., Nagpal, S., Leid, M., Rochette Egly, C., and Chambon, P. (1990). Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. *EMBO J.* 9, 4443–4454. doi:10.1002/j.1460-2075.1990. tb07895.x

Oeda, S., Hayashi, Y., Chan, T., Takasato, M., Aihara, Y., Obabayashima, K., et al. (2013). Induction of intermediate mesoderm by retinoic acid receptor signaling from differentiating mouse embryonic stem cells. *Int. J. Dev. Biol.* 57, 383–389. doi:10.1387/ ijdb.130058ma

Petrie, K., Urban-Wojciuk, Z., Sbirkov, Y., Graham, A., Hamann, A., and Brown, G. (2022). Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer. *Cancer Rep.* 3, e1284. doi:10.1002/cnr2.1284

Purton, L. E., Bernstein, I. D., and Collins, S. J. (1999). All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. *Blood* 94, 483–495. doi:10.1182/blood.v94.2.483.414k12_483_495

Purton, L. E., Dworkin, S., Olsen, G. H., Walkley, C. R., Fabb, S. A., Collins, S. J., et al. (2006). RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. *J. Exp. Med.* 203, 1283–1293. doi:10.1084/jem. 20052105

Randolph, R. K., and Simon, M. (1997). Metabolism of all-trans-retinoic acid by cultured human epidermal keratinocytes. *J. Lipid Res.* 3, 1374–1383. doi:10.1016/s0022-2275(20)37420-4

Rieger, M. A., Hoppe, P. S., Smejkal, B. M., Eitelhuber, A. C., and Schroeder, T. (2009). Hematopoietic cytokines can instruct lineage choice. *Science* 325, 217–218. doi:10.1126/ science.1171461

Rochette-Egly, C., Quland-Abdelghani, M., Staub, A., Pfister, V., Chambon, P., Gaub, M-P., et al. (1995). Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. *Mol. Endocrinol.* 9, 860–871. doi:10.1210/mend.9.7.7476969

Rochette-Egly, C. (2015). Retinoic acid signaling and mouse embryonic stem cell differentiation: Cross talk between genomic and non-genomic effects of RA. *Biochim. Biophys. Acta* 1851, 66–75. doi:10.1016/j.bbalip.2014.04.003

Roy, B., Taneja, R., and Chambon, P. (1995). Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor α (RAR α)-RAR β -or RAR γ -selective ligand in combination with a retinoid X receptor-specific ligand. *Mol. Cell. Biol.* 15, 6481–6487. doi:10.1128/MCB.15.12.6481

Ruberte, E., Dolle, P., Krust, A., Zelent, A., Morris-Kay, G., and Chambon, P. (1990). Specific spatial and temporal distribution of retinoic acid receptor gamma transcripts during mouse embryogenesis. *Development* 108, 213–222. doi:10.1242/dev.108.2.213

Sadhananthan, A. H., and Touson, A. (2005). Human embryonic stem cells and spontaneous differentiation. *Ital. J. Anat. Embryol.* 110, 151–157.

Sakashita, A., Nakamaki, T., Tsuruoke, N., Honma, Y., and Hozumi, M. (1991). Granulocyte colony-stimulating factor, not granulocyte-macrophage colonystimulating factor, co-operates with retinoic acid on the induction of functional N-formyl-methionyl-phenylalanine receptors in HL-60 cells. *Leukemia* 5, 26–31.

Samarut, E., Gaudin, C., Hughes, S., Gillet, B., de Bernard, S., Jouve, P-E., et al. (2014). Retinoic acid receptor subtype-specific transcriptomes in the early zebrafish embryo. *Mol. Endocrinol.* 28, 200–272.

Schier, A. F., and Shen, M. M. (2000). Nodal signalling in vertebrate development. *Nature* 403, 385–389. doi:10.1038/35000126

Schonberger, K., Obier, N., Romero-Mulero, M. C., Cauchy, P., Mess, J., Pavlovich, P. V., et al. (2022). Multilayer omics analysis reveals a nonclassical retinoic acid signaling axis that regulates hematopoietic stem cell identity. *Cell. Stem Cell.* 29, 131–148.e10. doi:10.1016/j.stem.2021.10.002

Silva, C., Wood, J. R., Salvador, L., Kostetskii, I., Williams, C. J., Strauss, J. F., III, et al. (2009). Expression profile of male germ cell-associated genes in mouse embryonic stem cell cultures treated with all-trans retinoic acid and testosterone. *Mol. Reprod. Dev.* 70, 11–21. doi:10.1002/mrd.20925

Sokol, S. Y. (2011). Maintaining embryonic stem cell pluripotency with Wnt signaling. *Development* 138, 4341-4350. doi:10.1242/dev.066209

Takenaga, M., Fukumoto, M., and Hari, Y. (2007). Regulated Nodal signaling promotes differentiation of the definitive endoderm and mesoderm from ES cells. *J. Cell. Sci.* 120, 2078–2090. doi:10.1242/jcs.004127

Taneja, R., Bouillet, P., Boylan, J. F., Gaub, M. P., Roy, B., Gudas, L. J., et al. (1995). Reexpression of retinoic acid receptor (RAR) gamma or overexpression of RAR alpha or RAR beta in RAR gamma-null F9 cells reveals a partial functional redundancy between the three RAR types. *Proc. Natl. Acad. Sci. U. S. A.* 92, 7854–7858. doi:10.1073/pnas.92. 17.7854

Tanoury, Z. A., Gaouar, S., Piskunov, A., Tao, Y., Urban, S., Just, B., et al. (2014). Phosphorylation of RAR $\gamma 2$ is critical for the neuronal differentiation of mouse embryonic stem cells. *J. Cell. Sci.* 127, 2095–2105. doi:10.1242/jcs.145979

Tanoury, Z. A., Piskunov, A., and Rochette-Egly, C. (2013). Vitamin A and retinoid signaling: Genomic and nongenomic effects. *J. Lipid Res.* 54, 1761–1775. doi:10.1194/jlr. R030833

Tollervey, J. R., and Lunyak, V. V. (2012). Epigenetics: Judge, jury and executioner of stem cell fate. *Epigenetics* 7, 823–840. doi:10.4161/epi.21141

Velten, L., Haas, S. F., Raffel, S., Blaszkiecz, S., Islam, S., Hennig, B. P., et al. (2017). Human haematopoietic stem cell lineage commitment is a continuous process. *Nat. Cell. Biol.* 19, 271–281. doi:10.1038/ncb3493

Vodyanik, M. A., Bork, J. A., Thomson, J. A., and Slukin, I. I. (2005). Human embryonic stem cell-derived CD34⁺ cells: Efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. *Blood* 15, 617–626. doi:10.1182/blood-2004-04-1649

Wai, H. A., Kawakami, K., Wada, H., Muller, F., Vernalis, A. B., Brown, G., et al. (2015). The development and growth of tissues derived from cranial neural crest and primitive mesoderm is dependent on the ligation status of retinoic acid receptor γ : Evidence that retinoic acid receptor γ functions to maintain stem/progenitor cells in the absence of retinoic acid. *Stem Cells Dev.* 24, 507–519. doi:10.1089/scd.2014.0235

Walkley, C. R., Yuan, Y. D., Chandraratna, R. A., and McArthur, G. A. (2002). Retinoic acid receptor antagonism *in vivo* expands the numbers of pre-cursor cells during granulopoiesis. *Leukemia* 16, 1763–1772. doi:10.1038/sj.leu.2402625

Xiu, L., Zhao, Y., Li, N., Zeng, J., Liu, J., Fu, Y., et al. (2022). High expression of RARG accelerates ovarian cancer progression by regulating cell proliferation. *Front. Oncol.* 12, 1063031. doi:10.3389/fonc.2022.1063031

Yamakowa, K., Koyangi-Aoi, M., Machinaga, A., Kakiuchi, N., Hirano, T., Kodama, Y., et al. (2022). Blockage of retinoic acid signalling via RARg suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression in G1-S phase. *Research Square*. doi:10.21203/rs.3.rs-2084078/v1

Ying, Q. L., Stavridis, M., Griffiths, P., Li, M., and Smith, A. (2003). Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. *Nat. Biotechnol.* 21, 183–186. doi:10.1038/nbt780

Yoon, S-H., Bae, M-R., La, H., Song, H., Hong, K., and Do, J-T. (2021). Efficient generation of neural stem cells from embryonic stem cells using a three-dimensional differentiation system. *Int. J. Mol. Sci.* 22, 8322. doi:10.3390/ijms22158322

Zhu, J., Heyworth, C. M., Glasow, A., Huang, Q-H., Petrie, K., Lanotte, M., et al. (2001). Lineage restriction of the RARalpha gene expression in myeloid differentiation. *Blood* 98, 2563–2567. doi:10.1182/blood.v98.8.2563

Zhu, H-H., Qin, Y-Z., Zhang, Z-L, Liu, Y-J., Wen, L-J., You, M. J., et al. (2023). A global study for acute myeloid leukemia with *RARG* rearrangement. *Blood Adv.*, 2022008364. Online ahead of print. doi:10.1182/bloodadvances.2022008364